All-cause mortality in pimavanserin and atypical antipsychotic users with Parkinson’s disease in Medicare
Objective: To assess all-cause mortality in Medicare beneficiaries with Parkinson’s disease (PD) receiving pimavanserin or atypical antipsychotics (AAs). Background: In PD patients, the lifetime prevalence…New compound increasing glucocerebrosidase activity on primary cell cultures obtained from patients with GBA-associated Parkinson’s disease
Objective: To determine whether new chemical modifications of the previously described allosteric GCase chaperone N607 (Aflaki E et.al Neurosc. 2016) increase GCase activity in monocyte-derived…Pharmacokinetics of Levodopa in patients with Parkinson’s disease: Efforts toward a predictive model
Objective: Our aim was to explore correlations between the pharmacokinetics of levodopa (LD) and clinical manifestation in patients with Parkinson’s disease (PD). Our goal was…A Case of Improved Psychotic Depression and Motor Symptoms in Parkinson’s Disease following Electroconvulsive Therapy (ECT)
Objective: To describe a case of motoric, affective, and psychotic symptoms improving in PD following ECT. Background: Parkinson’s disease (PD) is a neurodegenerative disease caused…Effectiveness and Tolerability of Mirabegron and Behavioral Therapy in Patients with Parkinson’s Disease and Overactive Bladder: A Prospective, Randomized, Placebo-Controlled Pilot Study
Objective: To assess safety, tolerability, and efficacy of mirabegron and Pelvic floor Exercise (PFE)-based behavioral therapy for the treatment of overactive bladder (OAB) in patients…Noninvasive brain stimulation to treat hypokinetic dysarthria in PD: A sham stimulation-controlled trial
Objective: To treat hypokinetic dysarthria (HD) in PD patients using multiple sessions repetitive transcranial magnetic stimulation (rTMS) Background: Based on results from our rTMS exploratory…Management of parkinsonian patients with long-term DBS and incomplete control of symptoms
Objective: We want to evaluate if apomorphine infusions can improve symptom control in PD patients with long standing DBS and functional decline. Background: Deep brain stimulation…Effectiveness of dopaminergic drugs on motor symptoms in Parkinson’s disease patients with deep brain stimulation of subthalamic nucleus
Objective: To compare the effectiveness of dopaminergic drugs on motor symptoms assessed by UPDRS- III in Parkinson’s disease patients pre and post deep brain stimulation…Anticholinergic Burden in Parkinson’s Disease Patients in India – A Hospital Based Study
Objective: To determine the cumulative anticholinergic burden in Indian Parkinson’s disease (PD) patients and to correlate the same with cognitive impairment and gait disturbance. Background:…Low dose Cabergoline for freezing of gait in advanced Parkinson’s disease – you can have your cake and eat it too!
Objective: To evaluate efficacy of cabergoline for treating FOG in advanced IPD. Background: FOG is a major cause of disability in advanced IPD. FOG responds…
- « Previous Page
- 1
- …
- 651
- 652
- 653
- 654
- 655
- …
- 1554
- Next Page »